Action Teva Pharmaceutical Indu... - TEV

Teva Pharmaceutical Industries Ltd (TEV) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

30,40

( -1,62% )

Prix Achat

30,20

Prix Vente

30,30

Volume échangé

280

30,40 Fourchette du Jour 31,20

13,00 Plage de 52 semaines 31,60

Clôture Veille

30,90

Ouverture

31,20

Dernière Transaction

30.4

Dernière heure de transaction

16:49:01

Volume moyen (3 m)

6 506

Volume financier

VWAP

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b...

Teva Releases Q2 2026 Aide Memoire

Teva Releases Q2 2026 Aide Memoire TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA...

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome NDA submission supported by positive Phase...

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET TEL AVIV, Israel and PARSIPPANY, N.J...

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy Ecopipam, an...

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in...

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and...

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea® AHZANTIVE® (aflibercept) is an...

Teva to Present at the Goldman Sachs Global Healthcare Conference

Teva to Present at the Goldman Sachs Global Healthcare Conference PARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva...

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	1	3.40136054422	29.4	31.2	28.8	7909	29.87324567	DE
4	1.8	6.29370629371	28.6	31.2	27	6266	29.20697288	DE
12	3.8	14.2857142857	26.6	31.5	26	6506	29.2386778	DE
26	2.8	10.1449275362	27.6	31.6	24.4	9009	28.20120364	DE
52	16.05	111.846689895	14.35	31.6	13	11117	23.09248653	DE
156	21.46	240.044742729	8.94	31.6	7.58	14601	16.17897323	DE
260	21.46	240.044742729	8.94	31.6	7.58	14601	16.17897323	DE

TEV - Frequently Asked Questions (FAQ)

What is the current Teva Pharmaceutical Industries Ltd share price?

The current share price of Teva Pharmaceutical Industries Ltd is 30,40 €

What is the 1 year trading range for Teva Pharmaceutical Industries Ltd share price?

Teva Pharmaceutical Industries Ltd has traded in the range of 13,00 € to 31,60 € during the past year

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Teva Pharmaceutical Industries Ltd (TEV)

Teva Pharmaceutical Industries Ltd (TEV) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

TEV Dernières nouvelles

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

Teva Releases Q2 2026 Aide Memoire

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

Teva to Present at the Goldman Sachs Global Healthcare Conference

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

TEV - Frequently Asked Questions (FAQ)

TEV Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Teva Pharmaceutical Industries Ltd (TEV)

Teva Pharmaceutical Industries Ltd (TEV) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

TEV Dernières nouvelles

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

Teva Releases Q2 2026 Aide Memoire

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

Teva to Present at the Goldman Sachs Global Healthcare Conference

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

TEV - Frequently Asked Questions (FAQ)

TEV Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités